José Luis López Lorenzo

Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

N. de Las Heras, P. Giraldo, J. Steegmann, 2015, American journal of hematology.

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

M. Tormo, F. Prósper, P. Martínez, 2021, Cancers.

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

P. Martínez, M. Sanz, J. Martínez-López, 2021, Leukemia & lymphoma.

Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD

A. Zanella, J. Segovia, P. Bianchi, 2022, American journal of hematology.

Lentiviral-mediated Gene Therapy for Adults and Children with Severe Pyruvate Kinase Deficiency: Results from an Ongoing Global Phase 1 Study

J. Segovia, J. Bueren, M. Zeini, 2022, Blood.

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

J. Cid, M. Mingot-Castellano, J. de la Rubia, 2022, Blood advances.

Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

J. Anguita, A. Balas, J. Vicario, 2023, Frontiers in Immunology.